Higher drug exposure in women due to lower renal and hepatic clearance and body composition can increase efficacy but also toxicity, highlighting the need to reassess dosing.
Three medical societies claim recent studies have overestimated the potential harms from lung cancer screening and may be deterring patients. Not everyone agrees.
EVERY day without a dedicated PhilHealth Z Benefit Package for lung cancer means more Filipino families face delayed ...
Daiichi Sankyo announced that the first patient has been dosed in the global phase 3 TROPION-Lung17 trial. The study is evaluating DATROWAY in patients with locally advanced or metastatic nonsquamous ...
When Jim Pantelas was diagnosed with lung cancer at 52, he felt that he had brought this disease upon himself. Having started ...
Post-treatment lung health is a longitudinal survivorship issue; nonregenerative parenchymal loss, radiation fibrosis, and ...
It can be surprising to learn that lung cancer can develop in people who have never smoked. In fact, up to 20% of lung ...
Incyte is looking to expand the use of its PD-1 blocker Zynyz to treat non-small cell lung cancer. The FDA’s rejection did ...
The past 30 years have seen tremendous progress in our fundamental understanding of lung cancer and the development of new treatment strategies,” senior researcher Dr. Cary Gross, a professor at Yale ...
In recent decades, lung cancer treatment has been transformed—new surgeries, new radiation techniques, and dramatically ...
LIMA — Pulmonologist Dr. Katie Capp warns her patients that cigarette smoke is the leading cause of preventable death ...
Suchan still needed chemotherapy and radiation, but Salgia credits Rybrevant for shrinking her tumors 60 to 70%. It specifically targets her cancer cells and revs up the immune system. For a year and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results